Overview

Antineoplaston Therapy in Treating Patients With Ependymoma

Status:
Terminated
Trial end date:
2000-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for patients with ependymoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of patients with ependymoma . PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with ependymoma.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute